Pharmaceuticals & Biotech U.K. Community

PureTech looks like a bargain on paper, but its setup may keep that value locked away: it’s listed in London while much of its work sits in the US biotech world, and big outside funding rounds can shrink what the parent ultimately owns. See why cash needs, slow-to-arrive royalty income, and a lack of bold moves like a US listing or buybacks could leave investors waiting far longer than expected.Read more

Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.Read more

Innovative niches in the market designed to tackle large problems. This company will be one to watch in the UK.Read more

March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts.Read more

AstraZeneca looks set to benefit as more people live longer, healthcare access expands in emerging markets, and medicine becomes more targeted to each patient. But looming copycat competition, tougher drug pricing rules, and rising research costs could test whether that growth really pays off.Read more

Oxford Biomedica is riding a wave of growing demand for the building blocks used to make new cell and gene therapies, and it says its capacity and late-stage customer work could translate into faster growth than many expect. The catch is that the business depends heavily on a small number of big customers while spending heavily to keep its technology and facilities competitive.Read more

HUTCHMED’s cancer drugs are growing beyond China, but tougher price cuts and a crowded field of look‑alike treatments could keep profits from scaling the way many expect. See why pricing pressure, heavy competition, and a still‑unproven next‑gen drug platform may limit how much upside the pipeline can really deliver.Read more

GSK is leaning into vaccines and specialty medicines, with a deep pipeline and a push into digital tools that could help it grow faster than many expect. But the story depends on key drug launches landing on time while it navigates tougher pricing pressure, patent cliffs, and ongoing legal overhangs.Read more

AstraZeneca’s next wave of cancer and specialty medicines, plus growing reach in fast-developing countries, could keep its business expanding even as older drugs mature. The big question is whether tougher drug pricing rules and copycat competition hit its biggest products before new launches can fully take over.Read more